Literature DB >> 26642256

Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

Judith E Karp1,2, Antonio C Wolff1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26642256      PMCID: PMC4707988          DOI: 10.1002/cncr.29613

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  13 in total

1.  Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

Authors:  Antonio C Wolff; Amanda L Blackford; Kala Visvanathan; Hope S Rugo; Beverly Moy; Lori J Goldstein; Keith Stockerl-Goldstein; Leigh Neumayer; Terry S Langbaum; Richard L Theriault; Melissa E Hughes; Jane C Weeks; Judith E Karp
Journal:  J Clin Oncol       Date:  2014-12-22       Impact factor: 44.544

2.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Authors:  R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert
Journal:  Blood       Date:  2014-12-30       Impact factor: 22.113

3.  Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.

Authors:  Eduard Schulz; Angelika Valentin; Peter Ulz; Christine Beham-Schmid; Karin Lind; Verena Rupp; Herwig Lackner; Albert Wölfler; Armin Zebisch; Werner Olipitz; Jochen Geigl; Andrea Berghold; Michael R Speicher; Heinz Sill
Journal:  J Med Genet       Date:  2012-05-31       Impact factor: 6.318

4.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

5.  Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

Authors:  Monica Castiglione-Gertsch; Anne O'Neill; Karen N Price; Aron Goldhirsch; Alan S Coates; Marco Colleoni; M Laura Nasi; Marco Bonetti; Richard D Gelber
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

6.  Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study.

Authors:  Helena M Verkooijen; Gerald Fioretta; Elisabetta Rapiti; Georges Vlastos; Isabelle Neyroud-Caspar; Pierre O Chappuis; Christine Bouchardy
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

7.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.

Authors:  Jane E Churpek; Rafael Marquez; Barbara Neistadt; Kimberly Claussen; Ming K Lee; Matthew M Churpek; Dezheng Huo; Howard Weiner; Mekhala Bannerjee; Lucy A Godley; Michelle M Le Beau; Colin C Pritchard; Tom Walsh; Mary-Claire King; Olufunmilayo I Olopade; Richard A Larson
Journal:  Cancer       Date:  2015-12-07       Impact factor: 6.860

8.  TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.

Authors:  Anna Stengel; Susanne Schnittger; Sandra Weissmann; Sabrina Kuznia; Wolfgang Kern; Alexander Kohlmann; Torsten Haferlach; Claudia Haferlach
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

9.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

Review 10.  The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.

Authors:  Bernard Friedenson
Journal:  BMC Cancer       Date:  2007-08-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.